منابع مشابه
What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines.
D uring November 2006 an updated version of the World Health Organisation/US National Heart Lung and Blood Institute global initiative for chronic obstructive lung disease (GOLD) guideline was made available online. We applaud those involved in creating a living document which has done much to raise the profile of this devastating disease. For many years chronic obstructive pulmonary disease (C...
متن کاملCOPD and GOLD stage I.
An abnormally low FEV 1 /FVC ratio is universally accepted as indicative of obstructive lung disease. Clearly, the choice of cutoff to defi ne abnormality is important. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) group set the lower limit of normal (LLN) at 0.7 irrespective of age, defi ning GOLD COPD stage I as FEV 1 /FVC below 0.7 and FEV 1 above 80% predicted. 1 In a re...
متن کاملA New Gold Standard – Pharmacological Interventions of Copd
The 2011 revision of the GOLD global strategy on COPD is a major paradigm shift in diagnosis and management of the disease. In particular, detailed assessment of current symptom control and future risk in terms of airflow limitation and exacerbation history, now allows more accurate categorisation of individual COPD patients. Pharmacological interventions are now directly linked to these catego...
متن کاملThe 2010 NICE COPD Guidelines: how do they compare with the GOLD guidelines?
The UK National Institute for Health and Clinical Excellence (NICE) has produced a 2010 partial update of its original 2004 Guidelines on COPD management. The definition of airflow obstruction has been altered to a post-bronchodilator FEV1/FVC ratio < 0.7 and the severity of airflow obstruction has been similarly aligned with the Global initiative for Obstructive Lung Disease (GOLD) guideline d...
متن کاملReal-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?
Clinical trials in chronic obstructive pulmonary disease (COPD) patients have shown that the long-term use of inhaled corticosteroids (ICS) in COPD patients reduced the number of exacerbations per patient per year and improved health status [1]. Early studies have suggested increased ICS efficacy in patients with low lung function and frequent exacerbations [2]. The efficacy was reinforced when...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bangladesh Journal of Medicine
سال: 2018
ISSN: 2408-8366,1023-1986
DOI: 10.3329/bjmed.v29i1.35405